Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model

Authors

Riti Sharan, Texas Biomedical Research Institute
Allison N Bucsan, Washington University School of Medicine in St. Louis
Shabaana A Khader, Washington University School of Medicine in St. Louis
et al

Journal

Journal of clinical investigation

Publication Date

2-1-2022

Volume

132

Issue

3

First Page

e153090

Document Type

Open Access Publication

DOI

10.1172/JCI153090

Rights and Permissions

Sharan R, Ganatra SR, Bucsan AN, Cole J, Singh DK, Alvarez X, Gough M, Alvarez C, Blakley A, Ferdin J, Thippeshappa R, Singh B, Escobedo R, Shivanna V, Dick EJ Jr, Hall-Ursone S, Khader SA, Mehra S, Rengarajan J, Kaushal D. Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model. J Clin Invest. 2022 Feb 1;132(3):e153090. doi: 10.1172/JCI153090. https://www.jci.org/articles/view/153090 © 2022, Sharan et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Recommended Citation

Sharan, Riti; Bucsan, Allison N; Khader, Shabaana A; and et al, "Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model." Journal of clinical investigation. 132, 3. e153090 (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11367